Given that anti-lymphangiogenesis therapy increases intratumoral PD-L1 antibody accumulation and alters the tumor immune microenvironment, its overall impact on the effectiveness of anti-PD-L1 antibodies is complex and warrants further investigation. The gene discussed is CD274; the disease is neoplasm.